Sugi Predict

Sugi Predict / Compounds / L-Kynurenine

L-Kynurenine

L-Kynurenine

SCHEMBL13969610

Nc1ccccc1C(=O)C[C@@H](N)C(=O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.64
▸ HIF1A Q16665 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ KYNU Q16719 2/20 0.49
▸ GAA P10253 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ALPI P09923 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ XIAP P98170 1/20 0.47
▸ SLC7A5 Q01650 1/20 0.47
▸ KMO O15229 3/20 0.45
▸ SLC1A3 P43003 2/20 0.45
▸ SLC1A2 P43004 2/20 0.45
▸ SLC1A1 P43005 2/20 0.45
▸ GRM2 Q14416 1/20 0.45
▸ GRM3 Q14832 1/20 0.45
▸ GRIK1 P39086 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kynurenine SCHEMBL288254 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL29349989 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL29396313 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL29415716 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL288989 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL20875 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL288988 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL20874 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL2181581 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL2368792 0.98 KDM4E (0.62) KDM4EHIF1ATDP1KYNUGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120019060-A Compounds and their use for filtering ultraviolet and/or high-energy visible light 索利奥美公司 2025-05-16 — — CN claimed
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
CN-120019060-A Compounds and their use for filtering ultraviolet and/or high-energy visible light 索利奥美公司 2025-05-16 — — CN disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 — — CN disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-11912989-B2 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-27 — — US disclosed
US-11912989-B2 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-27 — — US disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
US-20170209401-A1 A COMBINATION OF KYNURENINE AND ANTIGEN PRESENTING CELLS (APC) AS THERAPEUTICS AND METHODS FOR THEIR USE IN IMMUNE MODULATION THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-07-27 — — US disclosed
US-20170209401-A1 A COMBINATION OF KYNURENINE AND ANTIGEN PRESENTING CELLS (APC) AS THERAPEUTICS AND METHODS FOR THEIR USE IN IMMUNE MODULATION THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-07-27 — — US disclosed
US-20160304862-A1 ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-20 — — US disclosed
US-20160304862-A1 ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-20 — — US disclosed
EP-3078744-A1 ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES Chugai Seiyaku Kabushiki Kaisha (JP) 2016-10-12 — — EP disclosed
US-20160120857-A1 Anti-Fibrogenic Compounds, Methods and Uses Thereof THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-05-05 — — US disclosed
WO-2016044922-A1 A COMBINATION OF KYNURENINE AND ANTIGEN PRESENTING CELLS (APC) AS THERAPEUTICS AND METHODS FOR THEIR USE IN IMMUNE MODULATION THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-03-31 — — WO disclosed
WO-2015083764-A1 ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES 中外製薬株式会社 2015-06-11 — — WO disclosed
US-20090004112-A1 METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES USING NMDA RECEPTOR GLYCINE SITE ANTAGONISTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2009-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090004112-A1 METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES USING NMDA RECEPTOR GLYCINE SITE ANTAGONISTS GRIN2A, GRIN2B, GRIN2D KDM4E 2103/4885HIF1A 4735/4885TDP1 1326/4885
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 KDM4E 2322/4885HIF1A 2807/4885TDP1 1741/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB KDM4E 1466/4885HIF1A 3501/4885TDP1 705/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB KDM4E 1466/4885HIF1A 3501/4885TDP1 705/4885
US-20160120857-A1 Anti-Fibrogenic Compounds, Methods and Uses Thereof KYNU, AADAT, KMO KDM4E 1226/4885HIF1A 1302/4885TDP1 3248/4885
US-11912989-B2 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules MICA, CD69, CD74 KDM4E 4227/4885HIF1A 2805/4885TDP1 4088/4885
US-20170209401-A1 A COMBINATION OF KYNURENINE AND ANTIGEN PRESENTING CELLS (APC) AS THERAPEUTICS AND METHODS FOR THEIR USE IN IMMUNE MODULATION AADAT, IDO1, KYNU KDM4E 800/4885HIF1A 879/4885TDP1 2883/4885
US-20160304862-A1 ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES MICA, CD69, CD74 KDM4E 4227/4885HIF1A 2805/4885TDP1 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.